Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Bipolar Disorder | 253 | 2024 | 5130 | 14.710 |
Why?
|
Antipsychotic Agents | 160 | 2024 | 3081 | 10.490 |
Why?
|
Benzodiazepines | 119 | 2016 | 1138 | 8.870 |
Why?
|
Antimanic Agents | 46 | 2024 | 524 | 6.060 |
Why?
|
Pirenzepine | 33 | 2003 | 116 | 3.560 |
Why?
|
Valproic Acid | 34 | 2023 | 444 | 2.980 |
Why?
|
Lithium | 37 | 2023 | 600 | 2.800 |
Why?
|
Risperidone | 13 | 2021 | 383 | 2.260 |
Why?
|
Fluoxetine | 21 | 2014 | 733 | 2.250 |
Why?
|
Psychiatric Status Rating Scales | 106 | 2024 | 6029 | 2.220 |
Why?
|
Psychotic Disorders | 60 | 2023 | 3276 | 2.100 |
Why?
|
Antidepressive Agents | 28 | 2024 | 2913 | 1.890 |
Why?
|
Lithium Compounds | 15 | 2022 | 226 | 1.700 |
Why?
|
Lithium Carbonate | 11 | 2012 | 179 | 1.610 |
Why?
|
Double-Blind Method | 90 | 2024 | 12464 | 1.510 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 28 | 2017 | 1988 | 1.430 |
Why?
|
Piperazines | 8 | 2024 | 2552 | 1.410 |
Why?
|
Haloperidol | 24 | 2011 | 394 | 1.310 |
Why?
|
Schizophrenia | 53 | 2021 | 6983 | 1.160 |
Why?
|
Drug Therapy, Combination | 50 | 2023 | 6314 | 1.160 |
Why?
|
Depressive Disorder, Major | 18 | 2023 | 4818 | 1.150 |
Why?
|
Schizophrenic Psychology | 23 | 2016 | 1649 | 1.040 |
Why?
|
Depressive Disorder | 34 | 2018 | 3721 | 1.020 |
Why?
|
Treatment Outcome | 138 | 2024 | 65364 | 0.930 |
Why?
|
Affect | 16 | 2021 | 1495 | 0.920 |
Why?
|
Anticonvulsants | 19 | 2022 | 1922 | 0.860 |
Why?
|
Psychiatry | 7 | 2017 | 1716 | 0.840 |
Why?
|
Anti-Anxiety Agents | 3 | 2024 | 405 | 0.830 |
Why?
|
Adult | 237 | 2024 | 223583 | 0.830 |
Why?
|
Randomized Controlled Trials as Topic | 30 | 2024 | 10396 | 0.770 |
Why?
|
Severity of Illness Index | 46 | 2020 | 15944 | 0.760 |
Why?
|
Carbamazepine | 11 | 2012 | 224 | 0.750 |
Why?
|
Humans | 354 | 2024 | 767991 | 0.720 |
Why?
|
Psychotropic Drugs | 12 | 2019 | 881 | 0.720 |
Why?
|
Male | 254 | 2024 | 364641 | 0.710 |
Why?
|
Female | 254 | 2024 | 397113 | 0.660 |
Why?
|
Dibenzothiazepines | 5 | 2014 | 102 | 0.650 |
Why?
|
Mental Disorders | 13 | 2024 | 6875 | 0.640 |
Why?
|
Suicide | 10 | 2022 | 1606 | 0.610 |
Why?
|
Weight Gain | 17 | 2015 | 2359 | 0.590 |
Why?
|
Affective Disorders, Psychotic | 9 | 2006 | 187 | 0.560 |
Why?
|
Substance-Related Disorders | 17 | 2024 | 4423 | 0.540 |
Why?
|
Mentally Ill Persons | 1 | 2017 | 125 | 0.540 |
Why?
|
Suicide, Attempted | 11 | 2020 | 1413 | 0.530 |
Why?
|
Antidepressive Agents, Second-Generation | 4 | 2010 | 491 | 0.520 |
Why?
|
Suicidal Ideation | 8 | 2023 | 1467 | 0.520 |
Why?
|
Schizophrenia, Paranoid | 1 | 2016 | 103 | 0.510 |
Why?
|
Acute Disease | 25 | 2013 | 7241 | 0.510 |
Why?
|
Law Enforcement | 1 | 2017 | 112 | 0.510 |
Why?
|
Middle Aged | 137 | 2024 | 223422 | 0.510 |
Why?
|
Drug Administration Schedule | 26 | 2010 | 4857 | 0.500 |
Why?
|
Sleep Disorders, Circadian Rhythm | 1 | 2018 | 197 | 0.490 |
Why?
|
Patient Selection | 4 | 2020 | 4258 | 0.490 |
Why?
|
Placebos | 17 | 2009 | 1667 | 0.480 |
Why?
|
Depression | 21 | 2024 | 8231 | 0.480 |
Why?
|
Recurrence | 25 | 2018 | 8507 | 0.480 |
Why?
|
Antidepressive Agents, Tricyclic | 2 | 2015 | 430 | 0.460 |
Why?
|
Apathy | 2 | 2016 | 107 | 0.460 |
Why?
|
Research Design | 10 | 2020 | 6211 | 0.450 |
Why?
|
Drug Industry | 2 | 2013 | 791 | 0.450 |
Why?
|
Akathisia, Drug-Induced | 4 | 2008 | 66 | 0.450 |
Why?
|
Multilingualism | 1 | 2014 | 88 | 0.440 |
Why?
|
Delusions | 8 | 2021 | 300 | 0.430 |
Why?
|
Secondary Prevention | 11 | 2014 | 1474 | 0.420 |
Why?
|
Comorbidity | 31 | 2024 | 10590 | 0.410 |
Why?
|
Clinical Trials as Topic | 9 | 2017 | 8052 | 0.410 |
Why?
|
Signal Detection, Psychological | 1 | 2012 | 84 | 0.410 |
Why?
|
Dopamine Agonists | 1 | 2015 | 347 | 0.400 |
Why?
|
Advisory Committees | 6 | 2021 | 797 | 0.380 |
Why?
|
Adolescent | 79 | 2023 | 89155 | 0.380 |
Why?
|
Electroconvulsive Therapy | 4 | 2015 | 505 | 0.370 |
Why?
|
Hospitalization | 35 | 2020 | 10840 | 0.360 |
Why?
|
Personality Disorders | 5 | 2010 | 726 | 0.360 |
Why?
|
Cognition | 4 | 2019 | 7072 | 0.360 |
Why?
|
Anxiety Disorders | 8 | 2021 | 2748 | 0.360 |
Why?
|
International Cooperation | 3 | 2014 | 1434 | 0.360 |
Why?
|
Diffusion Tensor Imaging | 1 | 2021 | 2422 | 0.350 |
Why?
|
Outpatients | 6 | 2022 | 1600 | 0.350 |
Why?
|
Remission Induction | 13 | 2017 | 2409 | 0.340 |
Why?
|
Mental Health | 7 | 2024 | 3275 | 0.320 |
Why?
|
Follow-Up Studies | 51 | 2017 | 39345 | 0.320 |
Why?
|
Borderline Personality Disorder | 2 | 2014 | 767 | 0.320 |
Why?
|
Practice Guidelines as Topic | 6 | 2020 | 7445 | 0.320 |
Why?
|
Psychological Tests | 3 | 2015 | 643 | 0.310 |
Why?
|
Triazines | 5 | 2015 | 311 | 0.310 |
Why?
|
Mental Health Services | 3 | 2023 | 1733 | 0.310 |
Why?
|
Clozapine | 9 | 2000 | 509 | 0.310 |
Why?
|
Drug Evaluation | 1 | 2010 | 642 | 0.310 |
Why?
|
Trust | 1 | 2013 | 532 | 0.300 |
Why?
|
Polypharmacy | 3 | 2019 | 307 | 0.300 |
Why?
|
Personality Assessment | 2 | 2007 | 646 | 0.300 |
Why?
|
Adolescent Psychiatry | 1 | 2009 | 165 | 0.280 |
Why?
|
Ecology | 1 | 2007 | 105 | 0.270 |
Why?
|
Drug Therapy | 2 | 2007 | 504 | 0.270 |
Why?
|
Longitudinal Studies | 16 | 2020 | 14783 | 0.270 |
Why?
|
Substance Withdrawal Syndrome | 6 | 1998 | 628 | 0.270 |
Why?
|
Personality | 1 | 2010 | 559 | 0.270 |
Why?
|
Sample Size | 1 | 2009 | 846 | 0.260 |
Why?
|
Young Adult | 35 | 2019 | 60048 | 0.260 |
Why?
|
Child Psychiatry | 1 | 2009 | 230 | 0.260 |
Why?
|
Diagnostic Errors | 1 | 2013 | 1280 | 0.260 |
Why?
|
Perphenazine | 2 | 2004 | 33 | 0.250 |
Why?
|
Work | 2 | 2006 | 195 | 0.250 |
Why?
|
Age of Onset | 10 | 2011 | 3347 | 0.250 |
Why?
|
Psychometrics | 12 | 2016 | 3062 | 0.250 |
Why?
|
Thiazoles | 1 | 2012 | 1542 | 0.240 |
Why?
|
Drug Resistance | 2 | 2020 | 1598 | 0.240 |
Why?
|
Time Factors | 27 | 2014 | 40214 | 0.240 |
Why?
|
Prognosis | 18 | 2021 | 29979 | 0.230 |
Why?
|
Cognition Disorders | 9 | 2019 | 3977 | 0.230 |
Why?
|
Motivation | 1 | 2014 | 2020 | 0.230 |
Why?
|
Anxiety | 8 | 2023 | 4672 | 0.220 |
Why?
|
Affective Symptoms | 4 | 2024 | 418 | 0.220 |
Why?
|
Mood Disorders | 4 | 2012 | 1129 | 0.220 |
Why?
|
Terminology as Topic | 2 | 2009 | 1542 | 0.200 |
Why?
|
Injections, Intramuscular | 3 | 2020 | 554 | 0.200 |
Why?
|
Neurologic Examination | 3 | 2020 | 914 | 0.200 |
Why?
|
Spain | 3 | 2014 | 484 | 0.190 |
Why?
|
Latin America | 3 | 2014 | 416 | 0.190 |
Why?
|
Quality of Life | 12 | 2018 | 13489 | 0.190 |
Why?
|
Drug Partial Agonism | 1 | 2021 | 24 | 0.190 |
Why?
|
Dose-Response Relationship, Drug | 14 | 2012 | 10757 | 0.190 |
Why?
|
Prospective Studies | 30 | 2021 | 54924 | 0.190 |
Why?
|
Delayed-Action Preparations | 3 | 2020 | 968 | 0.190 |
Why?
|
Research | 1 | 2010 | 1979 | 0.190 |
Why?
|
Cholinergic Antagonists | 3 | 2020 | 166 | 0.180 |
Why?
|
Interprofessional Relations | 1 | 2007 | 997 | 0.180 |
Why?
|
International Classification of Diseases | 3 | 2013 | 936 | 0.180 |
Why?
|
Survival Analysis | 14 | 2016 | 10098 | 0.180 |
Why?
|
Ketamine | 2 | 2018 | 527 | 0.180 |
Why?
|
Health Services Needs and Demand | 2 | 2010 | 1406 | 0.180 |
Why?
|
Comparative Effectiveness Research | 5 | 2018 | 714 | 0.180 |
Why?
|
Japan | 5 | 2016 | 1418 | 0.170 |
Why?
|
Dopamine Antagonists | 1 | 2021 | 284 | 0.170 |
Why?
|
Cooperative Behavior | 1 | 2007 | 1512 | 0.170 |
Why?
|
Brief Psychiatric Rating Scale | 8 | 2009 | 108 | 0.170 |
Why?
|
Health Services | 1 | 2005 | 755 | 0.170 |
Why?
|
Emergency Services, Psychiatric | 1 | 2020 | 65 | 0.170 |
Why?
|
Risk Factors | 31 | 2019 | 74936 | 0.160 |
Why?
|
Evidence-Based Medicine | 3 | 2020 | 3701 | 0.160 |
Why?
|
Neuropsychological Tests | 11 | 2019 | 7140 | 0.160 |
Why?
|
Leukocyte Count | 4 | 2019 | 1609 | 0.160 |
Why?
|
Psychopathology | 3 | 2014 | 434 | 0.160 |
Why?
|
Pharmacoepidemiology | 6 | 1999 | 351 | 0.160 |
Why?
|
Basal Ganglia Diseases | 7 | 2007 | 145 | 0.160 |
Why?
|
Patient Admission | 6 | 2007 | 1365 | 0.160 |
Why?
|
Medication Therapy Management | 1 | 2020 | 131 | 0.160 |
Why?
|
Least-Squares Analysis | 3 | 2008 | 367 | 0.160 |
Why?
|
Aged | 39 | 2016 | 171446 | 0.150 |
Why?
|
Epidemiology | 2 | 2000 | 278 | 0.150 |
Why?
|
Health Care Costs | 2 | 2017 | 3239 | 0.150 |
Why?
|
Societies, Medical | 2 | 2014 | 3966 | 0.150 |
Why?
|
Prolactin | 3 | 2012 | 627 | 0.150 |
Why?
|
Medication Adherence | 2 | 2020 | 2187 | 0.150 |
Why?
|
Methamphetamine | 1 | 2020 | 167 | 0.150 |
Why?
|
Italy | 3 | 2013 | 856 | 0.150 |
Why?
|
Cross-Cultural Comparison | 3 | 2010 | 638 | 0.150 |
Why?
|
Disease Progression | 11 | 2021 | 13665 | 0.150 |
Why?
|
Narcissism | 1 | 1998 | 59 | 0.140 |
Why?
|
Retrospective Studies | 29 | 2023 | 81746 | 0.140 |
Why?
|
Anisotropy | 1 | 2021 | 1292 | 0.140 |
Why?
|
Disclosure | 1 | 2023 | 755 | 0.140 |
Why?
|
Injections | 1 | 2020 | 840 | 0.140 |
Why?
|
Insurance, Health | 2 | 2021 | 2517 | 0.140 |
Why?
|
Massachusetts | 7 | 2016 | 8888 | 0.140 |
Why?
|
Academic Medical Centers | 1 | 2007 | 2783 | 0.140 |
Why?
|
Placebo Effect | 4 | 2015 | 517 | 0.130 |
Why?
|
Binge-Eating Disorder | 1 | 2018 | 156 | 0.130 |
Why?
|
Leukopenia | 3 | 1996 | 212 | 0.130 |
Why?
|
Corpus Callosum | 1 | 2021 | 753 | 0.130 |
Why?
|
Health Status | 3 | 2012 | 4092 | 0.130 |
Why?
|
Immune System | 2 | 2017 | 799 | 0.120 |
Why?
|
Personality Inventory | 5 | 2015 | 1018 | 0.120 |
Why?
|
Recovery of Function | 2 | 2005 | 2981 | 0.120 |
Why?
|
Models, Psychological | 3 | 2011 | 825 | 0.120 |
Why?
|
Consensus | 5 | 2021 | 3210 | 0.120 |
Why?
|
Guidelines as Topic | 1 | 2001 | 1395 | 0.120 |
Why?
|
Actigraphy | 4 | 2023 | 527 | 0.120 |
Why?
|
Protons | 1 | 2020 | 1114 | 0.120 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 3729 | 0.120 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 2 | 2021 | 903 | 0.120 |
Why?
|
Capgras Syndrome | 1 | 2014 | 10 | 0.110 |
Why?
|
Patients | 1 | 2021 | 908 | 0.110 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2017 | 370 | 0.110 |
Why?
|
United States | 21 | 2021 | 73027 | 0.110 |
Why?
|
Risk | 7 | 2019 | 9609 | 0.110 |
Why?
|
Homicide | 1 | 2016 | 294 | 0.110 |
Why?
|
Drug Combinations | 3 | 2014 | 2089 | 0.110 |
Why?
|
Excitatory Amino Acid Antagonists | 1 | 2015 | 451 | 0.110 |
Why?
|
Predictive Value of Tests | 9 | 2017 | 15442 | 0.110 |
Why?
|
Social Adjustment | 5 | 2010 | 635 | 0.110 |
Why?
|
Receptors, Dopamine D2 | 1 | 2015 | 471 | 0.100 |
Why?
|
Acetaminophen | 1 | 2017 | 551 | 0.100 |
Why?
|
Episode of Care | 1 | 2013 | 127 | 0.100 |
Why?
|
Morbidity | 3 | 2020 | 1754 | 0.100 |
Why?
|
Drug Prescriptions | 2 | 2001 | 1667 | 0.100 |
Why?
|
Self Report | 3 | 2023 | 3773 | 0.100 |
Why?
|
Demography | 2 | 2015 | 1641 | 0.100 |
Why?
|
Length of Stay | 5 | 2000 | 6495 | 0.100 |
Why?
|
Chi-Square Distribution | 4 | 2010 | 3435 | 0.100 |
Why?
|
Psychomotor Agitation | 4 | 2019 | 307 | 0.100 |
Why?
|
Temporal Lobe | 5 | 2002 | 1726 | 0.100 |
Why?
|
Hospitals, Psychiatric | 6 | 1997 | 318 | 0.090 |
Why?
|
Diagnosis, Differential | 8 | 2017 | 13000 | 0.090 |
Why?
|
Single-Blind Method | 3 | 2013 | 1587 | 0.090 |
Why?
|
Multivariate Analysis | 4 | 2015 | 12075 | 0.090 |
Why?
|
Hypothyroidism | 1 | 2016 | 667 | 0.090 |
Why?
|
Sex Factors | 13 | 2017 | 10627 | 0.090 |
Why?
|
Guideline Adherence | 1 | 2001 | 2235 | 0.090 |
Why?
|
Publications | 1 | 2013 | 195 | 0.090 |
Why?
|
Databases, Factual | 3 | 2019 | 8082 | 0.090 |
Why?
|
Diagnosis, Dual (Psychiatry) | 2 | 2005 | 300 | 0.090 |
Why?
|
Circadian Rhythm | 2 | 2021 | 2591 | 0.090 |
Why?
|
Executive Function | 1 | 2019 | 1401 | 0.090 |
Why?
|
Drug Monitoring | 3 | 2020 | 964 | 0.090 |
Why?
|
Dysthymic Disorder | 1 | 2010 | 73 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 3 | 2016 | 6517 | 0.090 |
Why?
|
Epidemiologic Measurements | 1 | 2009 | 23 | 0.090 |
Why?
|
Decision Making | 2 | 2016 | 3952 | 0.080 |
Why?
|
Patient Transfer | 1 | 1997 | 790 | 0.080 |
Why?
|
Leukocytes | 1 | 2017 | 2035 | 0.080 |
Why?
|
Functional Laterality | 4 | 2002 | 2263 | 0.080 |
Why?
|
Hyperlipidemias | 1 | 2014 | 772 | 0.080 |
Why?
|
Memory | 1 | 2019 | 2208 | 0.080 |
Why?
|
Logistic Models | 6 | 2019 | 13289 | 0.080 |
Why?
|
Event-Related Potentials, P300 | 2 | 2002 | 149 | 0.080 |
Why?
|
Analysis of Variance | 6 | 2010 | 6228 | 0.080 |
Why?
|
Motor Activity | 2 | 2016 | 2711 | 0.080 |
Why?
|
Early Diagnosis | 3 | 2023 | 1193 | 0.080 |
Why?
|
ROC Curve | 3 | 2013 | 3628 | 0.080 |
Why?
|
Diabetes Mellitus | 2 | 2019 | 5887 | 0.080 |
Why?
|
Stereotyping | 1 | 2010 | 241 | 0.080 |
Why?
|
Attention | 1 | 2019 | 2424 | 0.080 |
Why?
|
Liver Function Tests | 2 | 2009 | 526 | 0.080 |
Why?
|
Disability Evaluation | 1 | 2016 | 1835 | 0.080 |
Why?
|
Brain | 7 | 2021 | 27366 | 0.080 |
Why?
|
Puerto Rico | 1 | 2009 | 380 | 0.080 |
Why?
|
Delirium | 2 | 1997 | 1697 | 0.070 |
Why?
|
Conflict of Interest | 1 | 2013 | 556 | 0.070 |
Why?
|
Kidney Diseases | 1 | 2019 | 2100 | 0.070 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 5536 | 0.070 |
Why?
|
Reproducibility of Results | 8 | 2016 | 20218 | 0.070 |
Why?
|
Emigrants and Immigrants | 1 | 2014 | 550 | 0.070 |
Why?
|
Thrombocytopenia | 2 | 1995 | 1179 | 0.070 |
Why?
|
Obesity | 6 | 2013 | 13091 | 0.070 |
Why?
|
Patient Compliance | 5 | 2006 | 2697 | 0.070 |
Why?
|
Review Literature as Topic | 1 | 2009 | 297 | 0.070 |
Why?
|
Adjustment Disorders | 1 | 2007 | 68 | 0.070 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 2271 | 0.070 |
Why?
|
Age Factors | 10 | 2011 | 18407 | 0.070 |
Why?
|
Appetite | 2 | 2006 | 247 | 0.070 |
Why?
|
Mass Screening | 2 | 2020 | 5458 | 0.070 |
Why?
|
Hallucinations | 3 | 2014 | 373 | 0.070 |
Why?
|
Long-Term Care | 2 | 2006 | 631 | 0.070 |
Why?
|
Linear Models | 3 | 2016 | 5884 | 0.070 |
Why?
|
Alcoholism | 5 | 2008 | 1980 | 0.070 |
Why?
|
Communicable Disease Control | 2 | 2024 | 857 | 0.070 |
Why?
|
Cost of Illness | 2 | 2021 | 1951 | 0.070 |
Why?
|
Accidents | 1 | 2007 | 164 | 0.070 |
Why?
|
Sleep Stages | 2 | 2006 | 705 | 0.070 |
Why?
|
Nervous System Diseases | 1 | 1997 | 1661 | 0.070 |
Why?
|
Aspartate Aminotransferases | 1 | 2007 | 414 | 0.060 |
Why?
|
Monoamine Oxidase Inhibitors | 3 | 1995 | 153 | 0.060 |
Why?
|
Proportional Hazards Models | 5 | 2015 | 12536 | 0.060 |
Why?
|
Marijuana Abuse | 2 | 2008 | 409 | 0.060 |
Why?
|
Cholesterol | 4 | 2007 | 2914 | 0.060 |
Why?
|
Psychotherapy | 1 | 2015 | 1655 | 0.060 |
Why?
|
Irritable Mood | 2 | 2017 | 196 | 0.060 |
Why?
|
Calcium Channel Blockers | 1 | 2008 | 688 | 0.060 |
Why?
|
Aspartic Acid | 2 | 2020 | 577 | 0.060 |
Why?
|
Socioeconomic Factors | 2 | 2013 | 7851 | 0.060 |
Why?
|
Headache | 2 | 2006 | 1263 | 0.060 |
Why?
|
Peer Review | 1 | 2007 | 218 | 0.060 |
Why?
|
Alanine Transaminase | 1 | 2007 | 606 | 0.060 |
Why?
|
Smoking | 2 | 2014 | 9089 | 0.060 |
Why?
|
Desipramine | 2 | 1995 | 183 | 0.060 |
Why?
|
Bupropion | 3 | 1995 | 303 | 0.060 |
Why?
|
Interview, Psychological | 3 | 2010 | 811 | 0.060 |
Why?
|
Fasting | 2 | 2007 | 1609 | 0.060 |
Why?
|
Lithium Chloride | 1 | 2004 | 83 | 0.060 |
Why?
|
Probability | 4 | 1994 | 2479 | 0.060 |
Why?
|
Cardiovascular Diseases | 3 | 2021 | 15660 | 0.060 |
Why?
|
Patient Dropouts | 3 | 2005 | 411 | 0.060 |
Why?
|
Patient Care Team | 1 | 1995 | 2521 | 0.060 |
Why?
|
Prevalence | 6 | 2018 | 15867 | 0.060 |
Why?
|
Rehabilitation, Vocational | 1 | 2003 | 70 | 0.050 |
Why?
|
Dizziness | 1 | 2006 | 269 | 0.050 |
Why?
|
Tamoxifen | 1 | 2008 | 966 | 0.050 |
Why?
|
Ambulatory Care | 6 | 2007 | 2781 | 0.050 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 3231 | 0.050 |
Why?
|
Delphi Technique | 2 | 2020 | 891 | 0.050 |
Why?
|
Treatment Refusal | 3 | 2006 | 433 | 0.050 |
Why?
|
Population Groups | 1 | 2024 | 209 | 0.050 |
Why?
|
Efficiency | 1 | 2006 | 479 | 0.050 |
Why?
|
Activities of Daily Living | 2 | 2010 | 2429 | 0.050 |
Why?
|
Matched-Pair Analysis | 2 | 2006 | 285 | 0.050 |
Why?
|
Sleep Apnea Syndromes | 1 | 1991 | 982 | 0.050 |
Why?
|
Drug Design | 1 | 2008 | 1045 | 0.050 |
Why?
|
Drug Approval | 1 | 2010 | 820 | 0.050 |
Why?
|
Speech Perception | 1 | 2007 | 510 | 0.050 |
Why?
|
Child | 10 | 2021 | 80906 | 0.050 |
Why?
|
Multicenter Studies as Topic | 2 | 2004 | 1736 | 0.050 |
Why?
|
Europe | 4 | 2013 | 3437 | 0.050 |
Why?
|
Sleep | 5 | 2021 | 4817 | 0.050 |
Why?
|
Principal Component Analysis | 4 | 2006 | 948 | 0.050 |
Why?
|
Odds Ratio | 5 | 2002 | 9666 | 0.050 |
Why?
|
Administration, Oral | 2 | 2001 | 4030 | 0.050 |
Why?
|
Cohort Studies | 13 | 2016 | 41749 | 0.050 |
Why?
|
Uric Acid | 1 | 2007 | 805 | 0.050 |
Why?
|
Syndrome | 3 | 2010 | 3271 | 0.050 |
Why?
|
Disorders of Excessive Somnolence | 2 | 2001 | 279 | 0.050 |
Why?
|
Nerve Fibers, Myelinated | 1 | 2006 | 952 | 0.050 |
Why?
|
Choice Behavior | 2 | 2017 | 848 | 0.040 |
Why?
|
Dyskinesia, Drug-Induced | 1 | 2001 | 165 | 0.040 |
Why?
|
Adult Survivors of Child Abuse | 1 | 2024 | 301 | 0.040 |
Why?
|
Argentina | 2 | 2011 | 249 | 0.040 |
Why?
|
Risk Assessment | 5 | 2021 | 24314 | 0.040 |
Why?
|
Amygdala | 2 | 2006 | 1380 | 0.040 |
Why?
|
Incidence | 8 | 2019 | 21532 | 0.040 |
Why?
|
Lorazepam | 1 | 2001 | 155 | 0.040 |
Why?
|
Attitude to Health | 2 | 2006 | 2024 | 0.040 |
Why?
|
Norepinephrine | 1 | 2023 | 898 | 0.040 |
Why?
|
Organ Size | 2 | 2021 | 2267 | 0.040 |
Why?
|
Drug Tolerance | 2 | 2019 | 365 | 0.040 |
Why?
|
New Mexico | 1 | 2020 | 81 | 0.040 |
Why?
|
Cross-Sectional Studies | 7 | 2021 | 26375 | 0.040 |
Why?
|
Vesicular Monoamine Transport Proteins | 1 | 2020 | 33 | 0.040 |
Why?
|
Certification | 1 | 1983 | 420 | 0.040 |
Why?
|
Chlorpromazine | 1 | 2000 | 111 | 0.040 |
Why?
|
Regression Analysis | 2 | 2007 | 6339 | 0.040 |
Why?
|
Cyclothymic Disorder | 1 | 2019 | 42 | 0.040 |
Why?
|
Cost Savings | 1 | 2005 | 904 | 0.040 |
Why?
|
Cross-Over Studies | 1 | 2006 | 2107 | 0.040 |
Why?
|
Seizures | 4 | 2014 | 2998 | 0.040 |
Why?
|
Sex Characteristics | 3 | 2016 | 2650 | 0.040 |
Why?
|
Employment | 3 | 2016 | 1110 | 0.040 |
Why?
|
Receptors, GABA | 1 | 2021 | 312 | 0.040 |
Why?
|
Chronic Disease | 7 | 2006 | 9384 | 0.040 |
Why?
|
Neuroimmunomodulation | 1 | 2021 | 187 | 0.040 |
Why?
|
Drug Utilization | 2 | 2002 | 1190 | 0.040 |
Why?
|
Marital Status | 1 | 2000 | 426 | 0.040 |
Why?
|
Pandemics | 3 | 2024 | 8748 | 0.040 |
Why?
|
Vulnerable Populations | 1 | 2024 | 718 | 0.040 |
Why?
|
Septum Pellucidum | 1 | 1998 | 55 | 0.040 |
Why?
|
Periodicity | 2 | 2014 | 348 | 0.040 |
Why?
|
Creatine | 1 | 2020 | 427 | 0.040 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2021 | 3780 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2005 | 2863 | 0.030 |
Why?
|
Interviews as Topic | 2 | 1997 | 2741 | 0.030 |
Why?
|
Glutamine | 1 | 2020 | 577 | 0.030 |
Why?
|
Thyroid Function Tests | 1 | 1997 | 289 | 0.030 |
Why?
|
Exercise | 1 | 2013 | 5955 | 0.030 |
Why?
|
Schizotypal Personality Disorder | 1 | 1998 | 289 | 0.030 |
Why?
|
Brain Damage, Chronic | 2 | 1994 | 265 | 0.030 |
Why?
|
1-Naphthylamine | 1 | 1996 | 48 | 0.030 |
Why?
|
Behavioral Research | 1 | 2016 | 52 | 0.030 |
Why?
|
Epidemiologic Methods | 1 | 2000 | 1326 | 0.030 |
Why?
|
Blood Glucose | 2 | 2007 | 6429 | 0.030 |
Why?
|
Combined Modality Therapy | 3 | 2003 | 8535 | 0.030 |
Why?
|
Counseling | 1 | 2023 | 1554 | 0.030 |
Why?
|
Imipramine | 1 | 1995 | 98 | 0.030 |
Why?
|
Personal Satisfaction | 1 | 2019 | 643 | 0.030 |
Why?
|
Brain Mapping | 2 | 2008 | 6685 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 8 | 2008 | 36742 | 0.030 |
Why?
|
Waist Circumference | 1 | 2018 | 935 | 0.030 |
Why?
|
Aged, 80 and over | 7 | 2011 | 59598 | 0.030 |
Why?
|
MEDLINE | 4 | 1995 | 119 | 0.030 |
Why?
|
Glutamic Acid | 1 | 2020 | 1189 | 0.030 |
Why?
|
Factor Analysis, Statistical | 2 | 2007 | 1001 | 0.030 |
Why?
|
Body Mass Index | 4 | 2018 | 13053 | 0.030 |
Why?
|
Telephone | 1 | 1997 | 630 | 0.030 |
Why?
|
Dibenzocycloheptenes | 1 | 2013 | 27 | 0.030 |
Why?
|
Dopamine | 1 | 2021 | 1592 | 0.030 |
Why?
|
Electroencephalography | 5 | 2002 | 6311 | 0.030 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 1997 | 496 | 0.030 |
Why?
|
Hippocampus | 3 | 2021 | 3786 | 0.030 |
Why?
|
Confidence Intervals | 2 | 1996 | 2923 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2013 | 416 | 0.030 |
Why?
|
Seasons | 1 | 1998 | 1524 | 0.030 |
Why?
|
Hospitals, General | 1 | 1997 | 806 | 0.020 |
Why?
|
Case-Control Studies | 3 | 2017 | 22287 | 0.020 |
Why?
|
Life Tables | 1 | 1991 | 367 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2008 | 5694 | 0.020 |
Why?
|
Needs Assessment | 1 | 2017 | 1141 | 0.020 |
Why?
|
Meta-Analysis as Topic | 2 | 2008 | 1363 | 0.020 |
Why?
|
Observation | 1 | 2013 | 310 | 0.020 |
Why?
|
Hypotension | 1 | 1997 | 888 | 0.020 |
Why?
|
Clonazepam | 1 | 1991 | 135 | 0.020 |
Why?
|
Patient-Centered Care | 1 | 2021 | 1444 | 0.020 |
Why?
|
Thyroid Gland | 1 | 1997 | 1172 | 0.020 |
Why?
|
Respiratory Therapy | 1 | 1991 | 125 | 0.020 |
Why?
|
Family Health | 1 | 2015 | 1255 | 0.020 |
Why?
|
Publication Bias | 1 | 2011 | 158 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2018 | 14718 | 0.020 |
Why?
|
Patient Preference | 1 | 2017 | 946 | 0.020 |
Why?
|
Colombia | 1 | 2010 | 287 | 0.020 |
Why?
|
Neural Pathways | 1 | 2021 | 3113 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2016 | 2357 | 0.020 |
Why?
|
Republic of Korea | 1 | 2011 | 591 | 0.020 |
Why?
|
Social Behavior | 1 | 1996 | 1147 | 0.020 |
Why?
|
Central Nervous System Diseases | 1 | 1994 | 519 | 0.020 |
Why?
|
Algorithms | 2 | 2021 | 14163 | 0.020 |
Why?
|
Health Personnel | 1 | 2023 | 3385 | 0.020 |
Why?
|
Eosinophilia | 1 | 1993 | 554 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2021 | 3619 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2013 | 1443 | 0.020 |
Why?
|
Body Weight | 1 | 2018 | 4628 | 0.020 |
Why?
|
Heart Arrest | 1 | 1997 | 1516 | 0.020 |
Why?
|
Quinolones | 1 | 2010 | 389 | 0.020 |
Why?
|
Pain | 2 | 2017 | 5100 | 0.020 |
Why?
|
Obsessive-Compulsive Disorder | 2 | 1996 | 1508 | 0.020 |
Why?
|
Software | 1 | 2021 | 4478 | 0.020 |
Why?
|
Gastrointestinal Diseases | 2 | 2009 | 1207 | 0.020 |
Why?
|
Brazil | 1 | 2010 | 1250 | 0.020 |
Why?
|
Geriatric Assessment | 1 | 1994 | 1422 | 0.020 |
Why?
|
Alcoholic Intoxication | 1 | 2007 | 171 | 0.020 |
Why?
|
Feeding Behavior | 1 | 2018 | 3205 | 0.020 |
Why?
|
Genetic Loci | 1 | 2015 | 2629 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2021 | 4530 | 0.020 |
Why?
|
Polysomnography | 1 | 2013 | 1869 | 0.020 |
Why?
|
Controlled Clinical Trials as Topic | 2 | 1998 | 187 | 0.020 |
Why?
|
Manuals as Topic | 1 | 1985 | 99 | 0.020 |
Why?
|
Factitious Disorders | 1 | 1985 | 39 | 0.020 |
Why?
|
Pilot Projects | 2 | 1996 | 8740 | 0.020 |
Why?
|
Databases, Bibliographic | 1 | 2006 | 128 | 0.020 |
Why?
|
Anemia | 1 | 1995 | 1514 | 0.020 |
Why?
|
Child Abuse | 1 | 1994 | 1091 | 0.020 |
Why?
|
Noise | 1 | 2007 | 295 | 0.020 |
Why?
|
North America | 1 | 2008 | 1289 | 0.010 |
Why?
|
Pulse | 1 | 2004 | 218 | 0.010 |
Why?
|
Pregnancy Complications | 1 | 1998 | 2972 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2021 | 6668 | 0.010 |
Why?
|
Canada | 2 | 1993 | 2129 | 0.010 |
Why?
|
Reference Values | 2 | 2006 | 4938 | 0.010 |
Why?
|
Caudate Nucleus | 1 | 2005 | 391 | 0.010 |
Why?
|
S-Adenosylmethionine | 1 | 1984 | 219 | 0.010 |
Why?
|
Residence Characteristics | 1 | 1992 | 2118 | 0.010 |
Why?
|
Psychomotor Disorders | 1 | 2003 | 149 | 0.010 |
Why?
|
Psychiatric Department, Hospital | 1 | 2003 | 133 | 0.010 |
Why?
|
Quality Improvement | 1 | 2017 | 3855 | 0.010 |
Why?
|
Medical Records | 2 | 1999 | 1409 | 0.010 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2004 | 719 | 0.010 |
Why?
|
Speech Disorders | 1 | 2003 | 179 | 0.010 |
Why?
|
Accidents, Traffic | 1 | 2007 | 818 | 0.010 |
Why?
|
Observer Variation | 1 | 2007 | 2618 | 0.010 |
Why?
|
Violence | 1 | 2007 | 933 | 0.010 |
Why?
|
Inflammation | 1 | 2021 | 10871 | 0.010 |
Why?
|
Self-Injurious Behavior | 1 | 2006 | 572 | 0.010 |
Why?
|
Adaptation, Psychological | 1 | 2010 | 2663 | 0.010 |
Why?
|
Dementia | 1 | 1994 | 2740 | 0.010 |
Why?
|
Epilepsy | 1 | 1994 | 3327 | 0.010 |
Why?
|
Models, Statistical | 1 | 2013 | 5107 | 0.010 |
Why?
|
Professional-Patient Relations | 1 | 1983 | 724 | 0.010 |
Why?
|
Preventive Health Services | 1 | 2003 | 570 | 0.010 |
Why?
|
Maryland | 1 | 1998 | 278 | 0.010 |
Why?
|
Animals | 1 | 2010 | 169222 | 0.010 |
Why?
|
Nuclear Family | 1 | 1998 | 311 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 2002 | 1666 | 0.010 |
Why?
|
New York | 1 | 1998 | 882 | 0.010 |
Why?
|
Hospital Bed Capacity | 1 | 1997 | 202 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 18062 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2015 | 16041 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2011 | 9536 | 0.010 |
Why?
|
Asthma | 1 | 2014 | 6273 | 0.010 |
Why?
|
Pain Measurement | 1 | 2005 | 3583 | 0.010 |
Why?
|
Confusion | 1 | 1997 | 278 | 0.010 |
Why?
|
Sertraline | 1 | 1996 | 209 | 0.010 |
Why?
|
Evoked Potentials, Auditory | 1 | 1998 | 533 | 0.010 |
Why?
|
Phosphocreatine | 1 | 1995 | 261 | 0.010 |
Why?
|
Abdominal Pain | 1 | 2001 | 1070 | 0.010 |
Why?
|
Pharmacy Service, Hospital | 1 | 1995 | 134 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2002 | 3553 | 0.010 |
Why?
|
Nausea | 1 | 1996 | 682 | 0.010 |
Why?
|
Choline | 1 | 1995 | 522 | 0.010 |
Why?
|
Paranoid Disorders | 1 | 1992 | 61 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2011 | 12795 | 0.010 |
Why?
|
Dissociative Disorders | 1 | 1994 | 235 | 0.010 |
Why?
|
History, 19th Century | 1 | 1994 | 714 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2003 | 5314 | 0.010 |
Why?
|
Patient Readmission | 2 | 1997 | 3288 | 0.010 |
Why?
|
Child Abuse, Sexual | 1 | 1994 | 400 | 0.010 |
Why?
|
Heart Rate | 1 | 2001 | 4215 | 0.010 |
Why?
|
Creatinine | 1 | 1995 | 1918 | 0.010 |
Why?
|
Blood Pressure | 1 | 2004 | 8540 | 0.000 |
Why?
|
Hospitals, Teaching | 1 | 1993 | 1157 | 0.000 |
Why?
|
Data Collection | 1 | 1997 | 3326 | 0.000 |
Why?
|
Arousal | 1 | 1993 | 1179 | 0.000 |
Why?
|
History, 20th Century | 1 | 1994 | 2766 | 0.000 |
Why?
|
Behavior Therapy | 1 | 1992 | 886 | 0.000 |
Why?
|
Sleep, REM | 1 | 1989 | 594 | 0.000 |
Why?
|
Neoplasms | 1 | 2014 | 22365 | 0.000 |
Why?
|
Housing | 1 | 1988 | 683 | 0.000 |
Why?
|
Internship and Residency | 1 | 1983 | 5952 | 0.000 |
Why?
|
Brain Diseases | 1 | 1992 | 1554 | 0.000 |
Why?
|
Reaction Time | 1 | 1989 | 2098 | 0.000 |
Why?
|
Periodicals as Topic | 1 | 1992 | 1465 | 0.000 |
Why?
|
Patient Discharge | 1 | 1993 | 3476 | 0.000 |
Why?
|
Liver | 1 | 1994 | 7574 | 0.000 |
Why?
|
Child, Preschool | 1 | 2001 | 42665 | 0.000 |
Why?
|
Cerebral Cortex | 1 | 1993 | 5813 | 0.000 |
Why?
|
Pregnancy | 1 | 1998 | 30260 | 0.000 |
Why?
|